Abstract
Datopotamab deruxtecan (Dato-DXd) is an antibody drug conjugate composed of a humanized anti-TROP2 IgG1 monoclonal antibody conjugated to a topoisomerase I inhibitor via a tetrapeptide-based cleavable linker. Dato-DXd demonstrated encouraging antitumor activity in patients (pts) with advanced/metastatic non-small cell lung cancer (NSCLC) from primary analysis results of TROPION-PanTumor01 (Garon E et al., WCLC2021). Here we report Japanese subgroup data from the NSCLC cohort of TROPION-PanTumor01.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
